Table 5.
Groups | ||||||
---|---|---|---|---|---|---|
Parameters | FC | FT | R1 | MC | MT | R2 |
Leukocyte (×103/mm3) |
5.17 ± 0.853 |
7.18 ± 0.385 |
4.7 – 12.98 a |
7.03 ± 0.677 |
7.70 ± 1.220 |
5.7 – 13.9 a |
Erythrocytes (×106/mm3) |
7.89 ± 0.395 |
8.60 ± 0.135 |
7.3 – 8.64 a |
9.56 ± 0.249 |
9.66 ± 0.230 |
6.7 – 8.6a |
Hemoglobin (g/dl) |
13.43 ± 0.685 |
14.87 ± 0.225 |
13.2 – 15.1 a |
15.59 ± 0.417 |
15.91 ± 0.309 |
12.8 – 15.9 a |
Hematocrit (%) |
42.93 ± 2.166 |
43.37 ± 0.569 |
39.1 – 48.5 a |
48.43 ± 1.206 |
45.60 ± 0.649 |
39.1 – 48.7 a |
VCM (fl) |
54.40 ± 0.727 |
49.87 ± 0.201*** |
49.1 – 62.5 a |
50.70 ± 0.439 |
47.21 ± 0.472*** |
50 – 59 a |
HCM (pg) |
17.00 ± 0.089 |
17.08 ± 0.065 |
16.6 – 18.9 a |
16.31 ± 0.112 |
16.5 ± 0.104 |
17.0 – 19.5 a |
CHCM (g/dl) |
31.28 ± 0.433 |
34.27 ± 0.071*** |
29.9 – 34.9 a |
32.17 ± 0.191 |
34.91 ± 0.265*** |
30.5 – 35.3 a |
Platelets (×106/mm3) |
1070 ± 74.760 |
1246 ± 59.830 |
757 – 1476 a |
1198 ± 41.10 |
1141 ± 73.77 |
837 – 1455 a |
Neutrophil (%) |
48.40 ± 7.259 |
36.97 ± 2.070 |
5.4 – 37.5 a |
45.84 ± 1.335 |
48.80 ± 3.384 |
17.1 – 47.9 a |
Lymphocyte (%) |
47.46 ± 5.432 |
57.73 ± 2.464 |
57.9 – 90.0 a |
48.26 ± 1.716 |
46.09 ± 2.773 |
48.7 – 78.1 a |
Monocyte (%) |
2.857 ± 0.739 |
3.43 ± 0.814 |
0.6 – 7.9 a |
3.47 ± 0.201 |
3.63 ± 0.432 |
1.0 – 6.5 a |
Eosinophil (%) | 1.60 ± 0.323 | 1.30 ± 0.206 | 0.2 – 4.5 a | 0.16 ± 0.031 | 0.08 ± 0.016 | 0.3 – 4.0 a |
FC (control female), FT (treated female), MC (control male), MT (treated male). N = 06. Data are expressed as mean ± S.D. * Indicate statistical difference between the control and treated group *p < 0.05, **p < 0.01 and ***p < 0.001 (test t). R1 (reference female); R2 (reference male); a Melo (2012).